Y-mAbs Therapeutics (YMAB) Competitors $8.54 +0.02 (+0.23%) Closing price 08/26/2025 04:00 PM EasternExtended Trading$8.53 -0.01 (-0.16%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock YMAB vs. JANX, EWTX, ARDX, HROW, SPRY, SDGR, AMPH, VERA, ABCL, and ETNBShould you be buying Y-mAbs Therapeutics stock or one of its competitors? The main competitors of Y-mAbs Therapeutics include Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), Ardelyx (ARDX), Harrow (HROW), ARS Pharmaceuticals (SPRY), Schrodinger (SDGR), Amphastar Pharmaceuticals (AMPH), Vera Therapeutics (VERA), AbCellera Biologics (ABCL), and 89BIO (ETNB). These companies are all part of the "pharmaceutical products" industry. Y-mAbs Therapeutics vs. Its Competitors Janux Therapeutics Edgewise Therapeutics Ardelyx Harrow ARS Pharmaceuticals Schrodinger Amphastar Pharmaceuticals Vera Therapeutics AbCellera Biologics 89BIO Y-mAbs Therapeutics (NASDAQ:YMAB) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership. Does the media favor YMAB or JANX? In the previous week, Janux Therapeutics had 3 more articles in the media than Y-mAbs Therapeutics. MarketBeat recorded 7 mentions for Janux Therapeutics and 4 mentions for Y-mAbs Therapeutics. Janux Therapeutics' average media sentiment score of 0.92 beat Y-mAbs Therapeutics' score of 0.90 indicating that Janux Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Y-mAbs Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer YMAB or JANX? Y-mAbs Therapeutics currently has a consensus price target of $9.62, indicating a potential upside of 12.67%. Janux Therapeutics has a consensus price target of $86.90, indicating a potential upside of 267.60%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than Y-mAbs Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Y-mAbs Therapeutics 2 Sell rating(s) 8 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.08 Which has preferable earnings & valuation, YMAB or JANX? Y-mAbs Therapeutics has higher revenue and earnings than Janux Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioY-mAbs Therapeutics$87.68M4.43-$29.67M-$0.50-17.08Janux Therapeutics$439K3,236.04-$68.99M-$1.80-13.13 Which has more volatility and risk, YMAB or JANX? Y-mAbs Therapeutics has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.86, meaning that its share price is 186% more volatile than the S&P 500. Do institutionals and insiders have more ownership in YMAB or JANX? 70.9% of Y-mAbs Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 19.7% of Y-mAbs Therapeutics shares are owned by insiders. Comparatively, 29.4% of Janux Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is YMAB or JANX more profitable? Janux Therapeutics has a net margin of 0.00% compared to Y-mAbs Therapeutics' net margin of -26.03%. Janux Therapeutics' return on equity of -11.48% beat Y-mAbs Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Y-mAbs Therapeutics-26.03% -24.60% -18.89% Janux Therapeutics N/A -11.48%-11.01% SummaryJanux Therapeutics beats Y-mAbs Therapeutics on 14 of the 17 factors compared between the two stocks. Get Y-mAbs Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding YMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart YMAB vs. The Competition Export to ExcelMetricY-mAbs TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$387.14M$3.07B$5.73B$9.74BDividend YieldN/A2.26%3.95%4.07%P/E Ratio-17.0820.5230.3326.09Price / Sales4.43352.87423.38106.20Price / CashN/A44.2437.7259.08Price / Book4.428.139.796.67Net Income-$29.67M-$54.08M$3.27B$265.43M7 Day Performance0.23%4.48%3.65%3.36%1 Month Performance79.04%3.64%3.83%0.39%1 Year Performance-43.70%7.34%32.34%19.43% Y-mAbs Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)YMABY-mAbs Therapeutics2.4565 of 5 stars$8.54+0.2%$9.62+12.7%-43.6%$387.14M$87.68M-17.08150JANXJanux Therapeutics2.7864 of 5 stars$25.53+1.7%$91.89+259.9%-49.0%$1.51B$10.59M-14.1830EWTXEdgewise Therapeutics2.4368 of 5 stars$14.00-1.1%$41.60+197.1%-27.7%$1.49BN/A-9.0360ARDXArdelyx4.146 of 5 stars$5.81-2.7%$11.50+97.9%-1.7%$1.44B$333.61M-25.2690News CoveragePositive NewsInsider TradeHROWHarrow3.439 of 5 stars$38.32-1.3%$64.67+68.8%-12.8%$1.44B$199.61M-153.28180Analyst RevisionSPRYARS Pharmaceuticals2.5729 of 5 stars$14.03-3.4%$31.00+121.0%+5.2%$1.44B$89.15M-28.6390SDGRSchrodinger2.9952 of 5 stars$20.05+3.5%$27.83+38.8%-5.8%$1.43B$207.54M-8.08790AMPHAmphastar Pharmaceuticals3.5159 of 5 stars$29.76-0.2%$31.50+5.8%-37.0%$1.39B$731.97M11.152,028Positive NewsAnalyst ForecastVERAVera Therapeutics3.8046 of 5 stars$21.80+1.2%$63.00+189.0%-41.8%$1.37BN/A-6.0940News CoveragePositive NewsABCLAbCellera Biologics2.1738 of 5 stars$4.67+1.7%$8.00+71.3%+62.5%$1.37B$28.83M-8.49500Gap UpETNB89BIO2.303 of 5 stars$9.44+2.3%$26.29+178.5%+0.4%$1.37BN/A-2.6140News CoverageAnalyst Forecast Related Companies and Tools Related Companies JANX Competitors EWTX Competitors ARDX Competitors HROW Competitors SPRY Competitors SDGR Competitors AMPH Competitors VERA Competitors ABCL Competitors ETNB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:YMAB) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredChase, Bank of America, Wells Fargo Preparing for BIG ChangeThanks to this brand-new law #S.1582 signed by President Trump… Jeff Brown believes the largest banks in Am...Brownstone Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access